Results for immunomodulatory translation from English to Maltese

no prior immunomodulatory exposure
ebda espożizzjoni immunomodulatorja preċedenti

s immunomodulatory activity in vitro.
huwa wera attività immunomodulatorja sinifikattiva in vitro. diċ

immunomodulatory effects have been observed in mice.
Ġew osservati effetti immunomodulatorji fil- ġrieden.

anti-neoplastic, immunomodulatory or immunosuppressive therapies
terapiji b’antineoplastiċi, immunomodulatorji jew b’immunosuppressivi

prior treatment with immunosuppressive or immunomodulatory therapies
kura fil-passat b’terapiji immunosoppressivi jew immunomodulatorji

immunomodulatory drugs may increase the risk of malignancy.
il-mediċini immunomodulatorji jistgħu jżidu r-riskju ta’ tumuri malinni.

it has demonstrated significant immunomodulatory activity in vitro.
huwa wera attività immunomodulatorja sinifikattiva in vitro.

immunomodulatory medicinal products may increase the risk of malignancy.
prodotti mediċinali immunomodulatorji jistgħu jżidu r-riskju ta’ tumuri malinni.

ceplene belongs to a group of medicines called immunomodulatory medicines.
ceplene jagħmel parti minn grupp ta' mediċini magħrufa bħala mediċini immunomodulatorji.

interferons are cytokines that mediate antiviral, antiproliferative and immunomodulatory activities.
l-interferoni huma ċitokini li jiffaċilitaw attivitajiet antivirali, antiproliferattivi u immunomodulatorji.

immunomodulatory medicinal products, including belimumab, may increase the risk of malignancy.
prodotti mediċinali immunomodulatorji, inkluż belimumab, jistgħu jżidu r-riskju ta’ mard malinn.

what ceplene is ceplene belongs to a group of medicines called immunomodulatory medicines.
x' inhu ceplene ceplene jagħmel parti minn grupp ta 'mediċini magħrufa bħala mediċini immunomodulatorji.

concomitant stable doses of oral aminosalicylates, and/or immunomodulatory agents were permitted.
dożi stabbli fl-istess ħin ta’ aminosalicylates orali, u/jew sustanzi immunomodulatorji kienu permessi.

in preclinical and clinical studies, tecfidera demonstrated anti-inflammatory and immunomodulatory properties.
fi studji kliniċi ta’ qabel l-użu kliniku u fi studji kliniċi, tecfidera wera propjetajiet kontra l- infjammazzjoni u immunomodulatorji.

immunomodulatory medicinal products may increase the risk of malignancy (see section 4.8).
prodotti mediċinali immunomodulatorji jistgħu jżidu r-riskju ta’ tumuri malinni (ara sezzjoni 4.8).

concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted.
dożi stabbli ta’ aminosalicylates orali, kortikosterojdi, u/jew aġenti immunomodulaturi mogħtija fl-istess ħin kienu permessi.

the mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.
il-mekkaniżmu ta’ l-azzjoni f’indikazzjonijiet oħrajn minbarra t-terapija tas-sostituzzjoni, ma jistgħux jiġu spjegati b’mod sħiħ, iżda jinkludu effetti immunomodulatorji.

interferons (ifns) are a group of endogenous glycoproteins endowed with immunomodulatory, antiviral and antiproliferative properties.
interferons (ifns) huma grupp ta ’ glikoproteini endoġeni li għandhom effetti immunodulatorji, kontra l- viruses u antiproliferattivi.

together, these immunomodulatory effects of daclizumab are believed to reduce cns pathology in ms and thereby reduce the occurrence of relapses and disability progression.
flimkien, dawn l-effetti immunomodulatorji ta’ daclizumab huma maħsuba li jnaqqsu l-patoloġija tas- cns f’ms u b’hekk inaqqsu l-okkorrenza ta’ rikaduti u l-progressjoni tad-diżabilità.

anti-neoplastic, immunomodulatory or immunosuppressive therapies should not be co-administered due to the risk of additive immune system effects.
terapiji anti-neoplastiċi, immunomodulatorji jew immunosoppressivi m’għandhomx jingħataw flimkien minħabba r-riskju ta’ effetti addittivi fuq is-sistema immuni.